Purpose: MicroRNAs (miRNA) that are strongly implicated in carcinogenesis have recently reshaped our understanding of the role of non–protein-coding RNAs. Here, we focused on the function and molecular mechanism of miR-202-3p and its potential clinical application in colorectal cancer.

Experimental Design:miR-202-3p expression was determined by quantitative reverse transcriptase PCR (qRT-PCR) in 94 colorectal cancer tissues and corresponding noncancerous tissues (NCT). Cell proliferation and colony formation assays in vitro and xenograft experiments in vivo were used to evaluate the effect of miR-202-3p on colorectal cancer cell proliferation. Luciferase assay and Western blot analysis were performed to validate the potential targets of miR-202-3p after the preliminary screening by online prediction and microarray analysis. The mRNA and protein levels of target genes were detected by qRT-PCR and immunohistochemical staining. The copy number of pre-miR-202 was measured by quantitative PCR.

Results: First, miR-202-3p was significantly downregulated in 46.7% colorectal cancer samples compared with NCTs. The overexpression of miR-202-3p inhibited colorectal cancer cell growth in vitro and repressed tumorigenesis in nude mice. Then, miR-202-3p downregulated ADP-ribosylation factor-like 5A (ARL5A) protein level by binding to its 3′ untranslated region, and knockdown of ARL5A phenocopied the proliferation inhibition effect of miR-202-3p. Furthermore, both of ARL5A mRNA and protein levels were upregulated in colorectal cancer samples compared with NCTs and high ARL5A protein levels predicted a poor prognosis.

Conclusions:miR-202-3p might function as a tumor suppressor in colorectal cancer, and ARL5A, the functional target of miR-202-3p in colorectal cancer, is a potential prognostic factor for colorectal cancer. Clin Cancer Res; 20(5); 1146–57. ©2013 AACR.

Translational Relevance

MicroRNAs (miRNA) are small, noncoding RNAs that are strongly implicated in carcinogenesis and have recently reshaped our understanding of the role of non–protein-coding RNAs. miRNAs have been argued to be used as potential diagnostic markers, prognostic factors, and therapeutic targets in the pathologic processes of tumorigenesis, while the biologic functions and molecular mechanisms of action of the majority of miRNAs remain largely unknown. In this study, miR-202-3p, which is frequently downregulated in human colorectal cancer, was identified as a potent repressor of proliferation. Reexpression of miR-202-3p expression inhibited colorectal cancer proliferation by silencing its direct target, ADP-ribosylation factor-like 5A (ARL5A), which was closely related to poor prognosis of patients with colorectal cancer. Although miRNA research is still in the early stages, the contribution of miRNAs to disease processes is becoming clear. Novel and expanded insights into miRNA deregulation will deepen our understanding of the complicated molecular pathogenesis of colorectal cancer and delineate new options for colorectal cancer treatment.

MicroRNAs (miRNA) are small noncoding RNAs (18–22 nt in length) that regulate the expression of target genes at the posttranscriptional level by binding to their target mRNAs (1, 2). Since their discovery in 1993, the number of verified miRNAs has grown rapidly, and the latest version of miRBase (release 20.0, June 2013, http://www.mirbase.org/) has annotated 2,578 mature miRNA sequences in the human genome. miRNAs are estimated to regulate up to one third of human genes at the posttranscriptional level (3). miRNA deregulation has been demonstrated to play a role in the pathologic processes of tumorigenesis (4, 5). Furthermore, miRNAs serve as potential diagnostic markers, prognostics factors, and therapeutic targets (6–9). Although miRNAs have been reported to be involved in human cancers, their biologic functions and molecular mechanisms remain largely unknown.

Colorectal cancer is the third most commonly diagnosed cancer in men and the second most commonly diagnosed cancer in women worldwide. Over 1.2 million new cancer cases occur annually, resulting in greater than 600,000 deaths each year (10). Despite recent advances in diagnostic and therapeutic measures, the prognoses of patients with colorectal cancer remain poor. Therefore, it is necessary to clarify the underlying molecular mechanisms and to identify specific biomarkers of colorectal cancer. The timely discovery of the importance of miRNAs is fortunate in this regard.

Over the past decade, the contribution of miRNAs (11), such as let-7 (12, 13), miR-17 (14, 15), miR-21 (16–19), miR-31 (20, 21), miR-95 (22), miR-101 (23, 24), miR-135 (25, 26), miR-137 (27), miR-139 (28, 29), miR-143 (30–32), miR-145 (31, 33), miR-155 (34), miR-183 (35), and miR-195 (36), to colorectal carcinogenesis has been examined. In a previous study, we determined that miR-95 is frequently overexpressed in colorectal cancer and acts as an important inducer of proliferation via the negative regulation of SNX1 expression (22). All these data highlight the importance of miRNAs in tumor development and provide new insights into the molecular mechanisms underlying carcinogenesis.

Our previous microarray data showed that miR-202-3p, a member of the let-7 family, was downregulated in colorectal cancer (22). In addition to colorectal cancer, miR-202-3p has also been reportedly deregulated in breast cancer and cervical squamous cell carcinoma (37, 38) and could inhibit cell proliferation in neuroblastomas (39, 40). These data suggest that miR-202-3p may play common roles in tumorigenesis. However, the detailed function and molecular mechanisms of miR-202-3p in human tumors have not been elucidated. In the present work, we confirmed that miR-202-3p expression was significantly decreased in colorectal cancer tissues compared with the noncancerous tissues (NCT) in an expanded colorectal cancer cohort. Moreover, we showed that miR-202-3p could inhibit cell proliferation by directly targeting ADP-ribosylation factor-like 5A (ARL5A) in colorectal cancer, and analysis of clinical tumor samples indicated that ARL5A is a new independent prognostic factor in colorectal cancer.

Human tissues and cell lines

A total of 94 pairs of human primary colorectal cancer tissues and their adjacent NCTs were collected between 2005 and 2008 at the Fudan University Shanghai Cancer Center. The tissue samples were immediately snap-frozen in liquid nitrogen and were histologically examined in a timely manner. All of the human materials were obtained with informed consent, and this project was approved by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center. The clinical information of the patients with colorectal cancer is included in Supplementary Table S1. HEK-293T cell line and six human colorectal cancer cell lines, including the HCT-8, HCT-116, LoVo, DLD1, SW480, SW620, were purchased from the American Type Culture Collection (ATCC). HCT-8 cells were cultured in RPMI-1640 medium, HCT-116 cells were cultured in McCoy's 5a medium, and LoVo cells were cultured in F12-K medium. DLD1 and HEK-293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM). SW480 and SW620 cells were maintained in Leibovitz's L-15 medium. All of these media (Invitrogen) were supplemented with 10% FBS (Gibco). The cells were incubated under the conditions recommended by ATCC.

DNA and RNA extraction and quantitative real-time RT-PCR

Tissue genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer's protocol. Total RNA, including miRNA, was extracted using the TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The concentrations of DNA and RNA were determined using a NanoDrop ND-1000 (NanoDrop), and aliquots of the samples were stored at −80°C. Relative DNA copy numbers were determined by quantitative PCR (qPCR) using SYBR Premix Ex Taq (TaKaRa). An amount of 50 ng DNA was used as template in a final volume of 20 μL with LINE-1 as an internal control (41–43). cDNA was synthesised with the PrimeScript RT Reagent Kit (TaKaRa) using 500 ng total RNA as template. qPCR analyses were conducted to quantitate mRNA relative expression using SYBR Premix Ex Taq (TaKaRa) with β-ACTIN as an internal control (44–46). TaqMan microRNA assays (Applied Biosystems) were used to determine the expression levels of miR-202-3p after reverse transcribing by sequence-specific primers (Applied Biosystems), and U6 small nuclear RNA was used as an internal control (47–50). The results of qPCR were defined from the threshold cycle (Ct), and relative expression levels were calculated by using the 2−ΔΔCt method (51). PCR was performed using an ABI 7900HT instrument (Applied Biosystems). The primers used for PCR analysis were listed in Supplementary Table S2.

Vector constructs

The human pri-miR-202 sequence was amplified from normal human genomic DNA by nested PCR using PrimerSTAR Premix (TaKaRa). The sequence was then cloned into the lentivirus expression vector pGIPZ (Thermofisher) to generate pGIPZ-miR-202. The predicted binding sites in the 3′ untranslated regions (UTR) of the potential target genes of miR-202-3p were amplified by nested PCR and cloned into the region directly downstream of a cytomegalovirus (CMV) promoter–driven firefly luciferase cassette in the pcDNA3.0 vector (pLuc). The mutant-type (MT) 3′ UTR of ARL5A, which carries the mutated sequence in the complementary site of the seed region of miR-202-3p, was generated from the pLuc-ARL5A 3′ UTR–wild-type (WT) plasmid by overlap-extension PCR. The sequences of the WT and MT 3′ UTRs were confirmed by DNA sequencing. The open reading frame (ORF) of ARL5A was amplified via nested PCR and cloned into the pLVX-IRES-Neo vector (Clontech). The primers and endonuclease sites used for the vector constructs are shown in Supplementary Table S2.

Lentivirus production and transduction

Virus particles were harvested 48 hours after cotransfecting pGIPZ-miR-202 and pLVX-ARL5A with the packaging plasmid ps-PAX2 and the envelope plasmid pMD2G into HEK-293T cells using Lipofectamine 2000 Reagent (Invitrogen). HCT-116 and LoVo cells were infected with recombinant lentivirus-transducing units plus 6 μg/mL polybrene (Sigma).

Oligonucleotide transfection

Small interfering RNA (siRNA) of miR-202-3p target genes (sequence information; Supplementary Table S3), as well as miR-202-3p/5p mimics and inhibitors (anti-miR-202-3p/5p, chemically modified antisense oligonucleotides designed to specifically target mature miR-202-3p/5p), were synthesised (Ribobio). Oligonucleotide transfection was performed using RNAiMAX reagents (Invitrogen) according to the manufacturer's instructions. The final concentration of the miR-202-3p/5p mimics or inhibitors in the transfection mixture was 50 nmol/L.

Cell proliferation and colony formation assays

Cell proliferation was quantified using the Cell Counting Kit-8 (CCK-8; Dojindo Laboratories) according to the manufacturer's instructions and the optical density (OD) value was obtained for determine the cell numbers. For the colony formation assays, 1,000 cells per well of HCT-116 and 1,500 cells per well of LoVo were plated into 6-well plates and incubated in medium containing 10% FBS for 2 weeks. The colonies were fixed with methanol and stained with 0.1% crystal violet in 20% methanol for 20 minutes. The number of colonies containing more than 30 cells was counted using an inverted microscope.

Tumor formation assay in a nude mouse model

Athymic male BALB/c nude mice were maintained under specific pathogen-free conditions in the Experimental Animal Department of Fudan University. The assay protocols were approved by the Shanghai Medical Experimental Animal Care Commission. HCT-116 or LoVo cells stably expressing miR-202 or the vector control were washed from subconfluent cell culture plates with PBS and then were resuspended with DMEM at a concentration of 1 × 107 cells/mL. A 0.1 mL aliquot of HCT-116 or 0.2 mL aliquot of LoVo-suspended cells was subcutaneously injected into the right flank of each mouse age 5 weeks (8 mice for each group). After transplantation, the growth of the subcutaneous tumors was assessed twice a week. Tumor size was monitored by measuring the length and width with callipers, and volumes were calculated with the formula: (L × W2) × 0.5, where L is the length and W is the width of each tumor. The mice were sacrificed after a period of 4 to 6 weeks, and the weight of subcutaneous tumors was recorded. HCT-116 cells, 24 hours after transfection with miR-202-3p mimics or negative control (NC), were also used for xenograft experiments following the procedures described above (52). The expression levels of miR-202-3p and ARL5A protein of cells used for tumor formation assay were examined (Supplementary Figs. S2B and S2C).

Cell migration assay

For the migration assays, 1 × 105 HCT-116 or 5 × 104 LoVo cells (stably expressed miR-202 or vector control) in 200 μL serum-free medium were placed onto the top chamber of each insert (BD Biosciences). After 36 (HCT-116) or 8 (LoVo) hours of incubation at 37°C, cells adhering to the lower membrane were stained with 0.1% crystal violet in 20% methanol, imaged, and counted using an IX71 inverted microscope (Olympus).

Microarray analysis

Genome-wide expression profiling was performed using an Agilent whole human genome oligo microarray chip (4 × 44 K) that contains more than 42,034 genes and transcripts (Agilent). An amount of 5 × 105 cells (HCT-116 or LoVo) were seeded in a 6-cm2 tissue culture dish and were transfected with miR-202-3p or control miRNA as described above. After propagating for 48 hours, total RNA was extracted from the cells using TRIzol reagent (Invitrogen). The RNA concentration was determined, and the integrity of RNA was verified using an Agilent 2100 Bioanalyzer (Agilent). Cy3-labeled cRNA was prepared with an Agilent One Color Spike Mix Kit (Agilent) and then hybridized by using a Gene Expression Hybridization Kit (Agilent) at 65°C for 17 hours. Signal intensity was calculated from digitized images captured by Laser Scanner (Agilent) and the chip data were analysed using the GeneSpring GX software (Agilent). An mRNA was designated as “downregulated” if its expression in miR-202-3p–transfected cells was 2-fold lower than that of the corresponding control cells.

Luciferase assay

Approximately 8,000 HEK-293T cells per well and 12,000 HCT-116 cells per well were plated into 96-well plates and were cotransfected with 50 nmol/L of miR-202-3p mimic (or NC), 50 ng of the luciferase reporter, and 5 ng of the pRL-CMV Renilla luciferase reporter using 0.5 μL per well Lipofectamine 2000 (Invitrogen). LoVo cells, plated into 96-well plates with 12,000 cells per well, were cotransfected with 100 nmol/L of miR-202-3p mimic (or NC), 200 ng of the luciferase reporter, and 20 ng of the pRL-CMV Renilla luciferase reporter using 1.25 μL per well X-tremeGENE Reagent (Roche). After a 48-hour incubation, the Firefly and Renilla luciferase activities were quantified using a dual-luciferase reporter assay (Promega).

Western blot analysis

Harvested proteins were first separated by 10% SDS–PAGE and then transferred to nitrocellulose membranes (Bio-Rad Laboratories). The membranes were blocked with 5% nonfat milk and incubated with a mouse anti-ARL5A polyclonal antibody at a dilution of 1:500 (Abgent) or a mouse anti–β-ACTIN monoclonal antibody at a dilution of 1:1,000 (Sigma). The membranes were subsequently incubated with a goat anti-mouse horseradish peroxidase secondary antibody (Sigma). The protein complex was detected using enhanced chemiluminescence reagents (Pierce). Endogenous β-ACTIN was used as the internal control.

Immunohistochemical staining

Tissue arrays were constructed using the 94 paired colorectal cancer tissues and NCTs. Immunohistochemical staining was performed on 4 μm sections of paraffin-embedded tissues to determine the expression level of ARL5A protein. In brief, the slides were incubated in ARL5A antibody (Abgent) diluted 1:200 at 4°C overnight. The subsequent steps were performed using the EnVision FLEX High pH visualisation system according to the manufacturer's instructions (Dako). The ARL5A staining intensity measurements are presented in Supplementary Fig. S2.

Statistical analyses

The results are presented as the mean values ± SEM. Overall survival (OS) rates were calculated actuarially according to the Kaplan–Meier method with log-rank test and were measured from the day of surgery. Differences between groups were estimated using the χ2 test, the Student t test, the Mann–Whitney U test, and the repeated-measures ANOVA test. Relationships were explored by the Spearman correlation. A value of P < 0.05 was considered statistically significant. SPSS 16.0 package (IBM) and Graphpad prism 5.0 software (GraphPad Software) were used for statistical analyses and scientific graphing, respectively.

Expression of miR-202-3p is decreased in human colorectal cancer tissues

miRNA expression profiling previously demonstrated that miR-202-3p is downregulated in colorectal cancers compared with NCTs (22). To further confirm this result, the expression level of mature miR-202-3p was examined using qRT-PCR in an expanded cohort of 94 patients with colorectal cancer. Consistent with the microarray data, miR-202-3p expression was remarkably downregulated in 44 of the 94 (46.7%) colorectal cancer tissues when compared with the corresponding NCTs (P < 0.001; Fig. 1A). However, there was no significant association between miR-202-3p expression in colorectal cancer tissues and gender, age, tumor location, tumor size, histologic classification, nodal status, or survival (P > 0.05; data not shown). In addition, miR-202-3p T:N expression ratios were weakly associated with OS of patients with colorectal cancer (SupplementaryFig. S1A).

Figure 1.

miR-202-3p expression was frequently reduced in colorectal cancer (CRC) as a result of DNA CNV. A, comparison of miR-202-3p expression levels in 94 matched pairs of colorectal cancer tissues and NCTs. The qRT-PCR results showed that miR-202-3p expression was significantly downregulated in tumor tissues (U6 small nuclear RNA used as an internal control). miR-202-3p expression was upregulated in 16.0%, downregulated in 46.7%, and unchanged in 37.2% of the colorectal cancer samples. B, pre-miR-202 copy numbers were determined for 37 matched colorectal cancer and NCT samples using qPCR. The copy number of pre-miR-202 was decreased in the tumor tissues compared with the NCTs (LINE-1 used as the internal control). The copy numbers of pre-miR-202 DNA were increased in 13.5%, decreased in 69.4%, and unchanged in 21.6% of the colorectal cancer samples compared with NCTs. C and D, miR-202-3p expression was positively correlated with the pre-miR-202 DNA copy number in both the colorectal cancer and the NCT samples.

Figure 1.

miR-202-3p expression was frequently reduced in colorectal cancer (CRC) as a result of DNA CNV. A, comparison of miR-202-3p expression levels in 94 matched pairs of colorectal cancer tissues and NCTs. The qRT-PCR results showed that miR-202-3p expression was significantly downregulated in tumor tissues (U6 small nuclear RNA used as an internal control). miR-202-3p expression was upregulated in 16.0%, downregulated in 46.7%, and unchanged in 37.2% of the colorectal cancer samples. B, pre-miR-202 copy numbers were determined for 37 matched colorectal cancer and NCT samples using qPCR. The copy number of pre-miR-202 was decreased in the tumor tissues compared with the NCTs (LINE-1 used as the internal control). The copy numbers of pre-miR-202 DNA were increased in 13.5%, decreased in 69.4%, and unchanged in 21.6% of the colorectal cancer samples compared with NCTs. C and D, miR-202-3p expression was positively correlated with the pre-miR-202 DNA copy number in both the colorectal cancer and the NCT samples.

Close modal

Downregulation of miR-202-3p in colorectal cancer tissues caused by DNA deletion

To confirm the hypothesis that downregulation of miR-202-3p in colorectal cancer tissues was partly caused by copy number variation of its coding sequence, we determined the pre-miR-202 copy number by qPCR in 37 pairs of the colorectal cancer tissues and NCTs. Interestingly, we found that the copy number of pre-miR-202 was lower in 64.9% (24 of 37) and higher in 13.5% (5 of 37) of the colorectal cancer tissues compared with their NCT counterparts (P < 0.05; Fig. 1B). Subsequent analysis showed that the pre-miR-202 copy numbers were related to the expression levels of mature miR-202-3p in both the colorectal cancer and NCT samples (P < 0.05; Fig. 1C and D).

miR-202-3p represses colorectal cancer cell proliferation in vitro and in vivo

The consistently low expression of miR-202-3p in colorectal cancer suggests it contributes to tumorigenesis. The expression of miR-202-3p was examined in 6 different colorectal cancer cell lines (SupplementaryFig. S1B). A cell proliferation assay revealed that overexpression of miR-202-3p significantly reduced the growth rate of HCT-116 and LoVo cells (P < 0.01; Fig. 2A), and a colony formation assay confirmed that miR-202 overexpression represses the proliferation of colorectal cancer cells (P < 0.01; Fig. 2B). In contrast, silencing of miR-202-3p expression with siRNA significantly promoted the growth of HCT-116 and LoVo cells (P < 0.01; Fig. 2A). Besides that, miR-202-5p did not show significant effect on the colorectal cancer cell growth (Supplementary Fig. S1C). To assess the function of miR-202 in vivo, a tumor formation assay in a nude mouse model was performed using HCT-116 and LoVo cells stably expressing miR-202 after lentiviral infection. Compared with the empty vector control, overexpression of miR-202 remarkably repressed tumorigenesis in nude mice (P < 0.01; Fig. 2C and D). Furthermore, overexpressed miR-202-3p by mimics transfecting in HCT-116 cells also repressed tumor growth in vivo (Supplementary Fig. S2A). In addition, transwell assay in HCT-116 or LoVo cells indicated that miR-202-3p may not significantly affect colorectal cancer migration (Supplementary Fig. S1D).

Figure 2.

miR-202-3p represses colorectal cancer cell growth in vitro and in vivo. A, miR-202-3p overexpression represses the proliferation of HCT-116 and LoVo cells. miR-202-3p knockdown enhanced the growth rate of HCT-116 and LoVo cells. The OD values were examined and the number of cells was determined using the Cell Counting Kit-8 Assay (*, P < 0.05; **, P < 0.01; ***, P < 0.001). B, the effect of miR-202 on colony formation was evaluated by crystal violet staining of miR-202 lentiviral vector-infected HCT-116 and LoVo cells. miR-202 overexpression represses the colony formation rates (P < 0.01). C and D, the effect of miR-202 on tumor formation in a nude mouse xenograft model. Lentiviral vector- and miR-202–infected HCT-116 cells (1 × 106) or LoVo cells (2 × 106) were injected s.c. into the right flank of each nude mouse. The tumor formation rate was 8 of 8 (Lenti-vector group) and 6 of 8 (Lenti-miR-202 group) for HCT-116 cells, and was 7 of 8 (NT group) and 5 of 8 (Lenti-miR-202 group) for LoVo cells. The tumor volume and weight of the miR-202-3p group was significantly decreased compared with the control group (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

Figure 2.

miR-202-3p represses colorectal cancer cell growth in vitro and in vivo. A, miR-202-3p overexpression represses the proliferation of HCT-116 and LoVo cells. miR-202-3p knockdown enhanced the growth rate of HCT-116 and LoVo cells. The OD values were examined and the number of cells was determined using the Cell Counting Kit-8 Assay (*, P < 0.05; **, P < 0.01; ***, P < 0.001). B, the effect of miR-202 on colony formation was evaluated by crystal violet staining of miR-202 lentiviral vector-infected HCT-116 and LoVo cells. miR-202 overexpression represses the colony formation rates (P < 0.01). C and D, the effect of miR-202 on tumor formation in a nude mouse xenograft model. Lentiviral vector- and miR-202–infected HCT-116 cells (1 × 106) or LoVo cells (2 × 106) were injected s.c. into the right flank of each nude mouse. The tumor formation rate was 8 of 8 (Lenti-vector group) and 6 of 8 (Lenti-miR-202 group) for HCT-116 cells, and was 7 of 8 (NT group) and 5 of 8 (Lenti-miR-202 group) for LoVo cells. The tumor volume and weight of the miR-202-3p group was significantly decreased compared with the control group (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

Close modal

Screening of candidate target genes of miR-202-3p

To explore the potential mechanism by which miR-202-3p represses the proliferation of colorectal cancer cells, we performed a microarray analysis to search for candidate genes regulated by miR-202-3p. Compared with the vector controls, a total of 823 downregulated genes (>2-fold change) were identified in the miR-202-3p–transfected LoVo cells (Supplementary Table S4). By comparing all of the downregulated genes with the candidate genes predicted by the TargetScan and Miranda programs, a total of 18 downregulated genes were selected out (Fig. 3A). Then the expression of these 18 genes was validated using qRT-PCR in both miR-202-3p-transfected HCT-116 and LoVo cells and 10 of these 18 genes were indeed downregulated by miR-202-3p (Fig. 3B). Then the recombinant plasmids with the 3′ UTR sequences of these 10 genes containing the predicted binding site sequence of miR-202-3p were constructed for luciferase assays. A panel of 4 candidate genes (ARL5A, LRIG3, HECTD2, and CPEB4) was selected because of their relatively decreased luciferase activity in miR-202-3p–transfected cells (Fig. 3C). Subsequently, a preliminary cell proliferation assay was performed on HCT-116 and LoVo cells transfected with the pertinent siRNAs (to eliminate the off-target effects of siRNAs by qRT-PCR; Supplementary Fig. S3B). ARL5A, LRIG3, and CPEB4 were found to be associated with cell growth, and depleting ARL5A expression showed the most obvious growth repression effect (Fig. 3D). In addition, ARL5A mRNA expression was upregulated in colorectal cancer tissues compared with NCTs in small samples, whereas LRIG3 mRNA was not (n = 30; Supplementary Fig. S3C).

Figure 3.

Screening of candidate target genes of miR-202-3p in colorectal cancer. A, initial screening of miR-202-3p target genes in HCT-116 and LoVo using a microarray assay and bioinformatics predictions. A total of 18 downregulated genes were selected out. B, validation of the microarray results in both HCT-116 and LoVo cells using qRT-PCR. A panel of 10 genes were indeed downregulated by miR-202-3p. C, four candidate genes (ARL5A, LRIG3, HECTD2, and CPEB4) were selected due to their relatively decreased luciferase activity in miR-202-3p–transfected cells (-1, -2, -3 following the gene names represent the 3′ UTR plasmids cloned with different predicted binding sites). D and E, proliferation assays performed on HCT-116 and LoVo cells transfected with siRNA directed against 4 candidate genes. Depleted ARL5A expression showed the most obvious growth repression effect.

Figure 3.

Screening of candidate target genes of miR-202-3p in colorectal cancer. A, initial screening of miR-202-3p target genes in HCT-116 and LoVo using a microarray assay and bioinformatics predictions. A total of 18 downregulated genes were selected out. B, validation of the microarray results in both HCT-116 and LoVo cells using qRT-PCR. A panel of 10 genes were indeed downregulated by miR-202-3p. C, four candidate genes (ARL5A, LRIG3, HECTD2, and CPEB4) were selected due to their relatively decreased luciferase activity in miR-202-3p–transfected cells (-1, -2, -3 following the gene names represent the 3′ UTR plasmids cloned with different predicted binding sites). D and E, proliferation assays performed on HCT-116 and LoVo cells transfected with siRNA directed against 4 candidate genes. Depleted ARL5A expression showed the most obvious growth repression effect.

Close modal

ARL5A is a direct target of miR-202-3p in colorectal cancer

To determine whether ARL5A is a direct target of miR-202-3p in colorectal cancer, we constructed a recombinant plasmid containing the ARL5A 3′ UTR sequence with a mutated binding site sequence (Fig. 4B). Luciferase activity was no longer reduced in cells (HEK-293T, HCT-116, LoVo) transfected with the mutant 3′ UTR plasmid versus the WT 3′ UTR plasmid (Fig. 4A). In concordance with these results, endogenous ARL5A protein levels were downregulated in miR-202-3p–overexpressing cell lines and were restored when the expression of miR-202-3p was repressed (Fig. 4C).

Figure 4.

miR-202-3p suppresses ARL5A expression by directly targeting its 3′ UTR. A, relative luciferase activity assays of luciferase reporters with ARL5A WT or MT 3′ UTR were performed in cells (HEK-293T, HCT-116, and LoVo) after cotransfection with pGIPZ-miR-202 plasmids. Luciferase activity was determined 48 hours after transfection and normalized to the Renilla luciferase activity. The luciferase activity generated by pLUC in each experiment was set as 1. B, schematic of the WT or MT 3′ UTRs of the ARL5A vector constructs. The complementary site of the seed region of miR-202-3p was selected for mutation. C, endogenous ARL5A expression was suppressed by miR-202-3p. The protein levels of ARL5A were determined by Western blot assays in HCT-116 and LoVo cells infected with miR-202-3p or control lentiviruses, the miR-202-3p inhibitor (anti-miR-202-3p), or the negative control (anti-NC). β-ACTIN served as an internal control.

Figure 4.

miR-202-3p suppresses ARL5A expression by directly targeting its 3′ UTR. A, relative luciferase activity assays of luciferase reporters with ARL5A WT or MT 3′ UTR were performed in cells (HEK-293T, HCT-116, and LoVo) after cotransfection with pGIPZ-miR-202 plasmids. Luciferase activity was determined 48 hours after transfection and normalized to the Renilla luciferase activity. The luciferase activity generated by pLUC in each experiment was set as 1. B, schematic of the WT or MT 3′ UTRs of the ARL5A vector constructs. The complementary site of the seed region of miR-202-3p was selected for mutation. C, endogenous ARL5A expression was suppressed by miR-202-3p. The protein levels of ARL5A were determined by Western blot assays in HCT-116 and LoVo cells infected with miR-202-3p or control lentiviruses, the miR-202-3p inhibitor (anti-miR-202-3p), or the negative control (anti-NC). β-ACTIN served as an internal control.

Close modal

Upregulation of ARL5A is closely correlated with miR-202-3p expression and poor prognosis in colorectal cancer

To study the relationship between miR-202-3p and ARL5A in human colorectal cancer, we measured the mRNA and protein expression levels of ARL5A in the 94 paired colorectal cancer and NCT samples using qRT-PCR and immunohistochemistry methods, respectively. Compared with the matched NCTs, ARL5A mRNA expression was upregulated in colorectal cancer tissues (P < 0.05; Fig. 5A) and inversely correlated with miR-202-3p levels (Supplementary Fig. S4B). ARL5A protein was overexpressed in 56.4% (53 of 94) of the colorectal cancer tissues compared with the matched NCTs (P < 0.05; Fig. 5B) and clearly negatively correlated with miR-202-3p expression levels (P < 0.05; Fig. 5C). More importantly, enhanced immunoreactivity of ARL5A in colorectal cancer tissues was inversely correlated with OS and suggested a poor prognosis for the patients with colorectal cancer (P < 0.01; Fig. 5D). In addition, higher ARL5A protein levels in colorectal cancers compared with NCTs also indicated poor prognosis (Supplementary Fig. S4C). No association was observed between the intensity of ARL5A staining and tumor size, grade, stage, or lymph node metastasis (P > 0.05).

Figure 5.

ARL5A was overexpressed in colorectal cancer and its level closely correlated with the level of miR-202-3p. A, ARL5A mRNA expression level was significantly increased in the 94 colorectal cancer tissues compared with matched NCT samples determined by qRT-PCR. β-ACTIN mRNA served as the internal control. B, immunohistochemical staining of ARL5A in the tumor tissues and the corresponding normal colon epithelia. Brown cytoplasmic ARL5A staining was observed in colorectal cancer tissues but was nearly absent in the normal epithelia (original magnification, ×100 or ×400). ARL5A expression is frequently increased in the tumor tissues (n = 94) compared with the matched NCTs, with overexpression in 56.4%, reduced expression in 25.5%, and unchanged expression in 18.1% of the colorectal cancer tissues. Statistical analyses of the cases grouped according to the ARL5A scoring. Statistical significance was assessed using the χ2 test. C, the level of expression of ARL5A correlated negatively with the miR-202-3p expression levels in the tumor tissues. D, OS analysis based on the expression level of ARL5A. The groups were ranked according to the ARL5A staining intensity. Patients who scored 0, 1, or 2 were included in the low-expression group, whereas those who scored 3 were included in the high-expression group. The percentage of OS in the ARL5A low-expression group was significantly higher than that of patients in the ARL5A high-expression group.

Figure 5.

ARL5A was overexpressed in colorectal cancer and its level closely correlated with the level of miR-202-3p. A, ARL5A mRNA expression level was significantly increased in the 94 colorectal cancer tissues compared with matched NCT samples determined by qRT-PCR. β-ACTIN mRNA served as the internal control. B, immunohistochemical staining of ARL5A in the tumor tissues and the corresponding normal colon epithelia. Brown cytoplasmic ARL5A staining was observed in colorectal cancer tissues but was nearly absent in the normal epithelia (original magnification, ×100 or ×400). ARL5A expression is frequently increased in the tumor tissues (n = 94) compared with the matched NCTs, with overexpression in 56.4%, reduced expression in 25.5%, and unchanged expression in 18.1% of the colorectal cancer tissues. Statistical analyses of the cases grouped according to the ARL5A scoring. Statistical significance was assessed using the χ2 test. C, the level of expression of ARL5A correlated negatively with the miR-202-3p expression levels in the tumor tissues. D, OS analysis based on the expression level of ARL5A. The groups were ranked according to the ARL5A staining intensity. Patients who scored 0, 1, or 2 were included in the low-expression group, whereas those who scored 3 were included in the high-expression group. The percentage of OS in the ARL5A low-expression group was significantly higher than that of patients in the ARL5A high-expression group.

Close modal

miR-202-3p represses proliferation by directly targeting ARL5A in colorectal cancer

To further clarify whether targeting of ARL5A might mediate the inhibition of cell proliferation in miR-202-3p–overexpressing colorectal cancer cells, we performed a series of functional restoration assays using HCT116 and LoVo cells. First, we inhibited ARL5A expression with siRNA and found that ARL5A-depleted cells exhibited decreased proliferation, which strongly indicated that silencing ARL5A phenocopied the proliferation-repressing effect of miR-202-3p (Fig. 6A). Next, cotransfection experiments using ARL5A and miR-202-3p siRNAs also showed that miR-202-3p knockdown did not enhance the growth rate of colorectal cancer cells when ARL5A expression had been silenced by siRNA (Fig. 6B). Moreover, ARL5A overexpression (overexpressed ORF without 3′ UTR) promoted cell proliferation, which could not be restored by either exogenous or endogenous overexpression of miR-202-3p (Fig. 6C and D).

Figure 6.

miR-202-3p represses colorectal cancer cell growth by downregulating ARL5A expression. The cell proliferation rate was determined 96 hours after transfection, and the level of ARL5A protein expression was detected 48 hours after transfection. A, ARL5A knockdown using siRNA significantly repressed colorectal cancer cell proliferation; overexpression of miR-202-3p did not suppress cell proliferation in ARL5A-depleted HCT-116 or LoVo cells. B, miR-202-3p knockdown restored the endogenous expression of ARL5A protein and promoted colorectal cancer cell growth, but did not promote cell proliferation in ARL5A-depleted HCT-116 or LoVo cells. C and D, overexpression of ARL5A (ORF without 3′ UTR) significantly promoted cell growth and abrogated the miR-202-3p–induced cell growth inhibition in HCT-116 and LoVo cells. The miR-202-3p was overexpressed by mimics transfection (C) or lentivirus (lenti) transduction. To get ARL5A ORF and/or miR-202 overexpressed stable cells, HCT-116 or LoVo cells were infected with Lenti-ARL5A ORF and/or Lenti-miR-202 virus particles (D).

Figure 6.

miR-202-3p represses colorectal cancer cell growth by downregulating ARL5A expression. The cell proliferation rate was determined 96 hours after transfection, and the level of ARL5A protein expression was detected 48 hours after transfection. A, ARL5A knockdown using siRNA significantly repressed colorectal cancer cell proliferation; overexpression of miR-202-3p did not suppress cell proliferation in ARL5A-depleted HCT-116 or LoVo cells. B, miR-202-3p knockdown restored the endogenous expression of ARL5A protein and promoted colorectal cancer cell growth, but did not promote cell proliferation in ARL5A-depleted HCT-116 or LoVo cells. C and D, overexpression of ARL5A (ORF without 3′ UTR) significantly promoted cell growth and abrogated the miR-202-3p–induced cell growth inhibition in HCT-116 and LoVo cells. The miR-202-3p was overexpressed by mimics transfection (C) or lentivirus (lenti) transduction. To get ARL5A ORF and/or miR-202 overexpressed stable cells, HCT-116 or LoVo cells were infected with Lenti-ARL5A ORF and/or Lenti-miR-202 virus particles (D).

Close modal

It is well known that miRNAs are key components of tumorigenesis, as they participate in many cellular processes including cell proliferation, differentiation, and death. The effects of miRNAs are based on their regulation of the expression of many cancer-related genes through posttranscriptional repression. As we previously reported, a panel of miRNAs was altered in colorectal cancer tissues, suggesting that variations in the expression of miRNAs are common events in colorectal tumorigenesis (1, 5, 11). We previously reported that miR-95, which seems to be an oncogenic miRNA in colorectal cancer, promoted cell proliferation by directly targeting SNX1 (22). In addition to upregulated miRNAs, downregulated miRNAs also contribute notably to tumorigenesis. miR-139-5p, miR-145, miR-125a, and miR-133a have been reported to be tumor suppressors whose precise underlying mechanisms have been identified as they relate to the development of colorectal cancer (31, 53–55).

With the aim of finding new colorectal cancer-associated miRNAs, we focused on miR-202-3p (previously named miR-202 before miRBase release 16.0), a target that was found to be significantly downregulated in colorectal cancer samples in our previous profiling data (22). miR-202-3p is highly conserved across animal species and is now considered a member of the let-7 family, which consists of tumor suppressors that target k-RAS and MYCN (12, 39, 40). Consistent with the role of let-7 family members, in this study, we found that miR-202-3p repressed cell proliferation and colony formation in colorectal cancer via its direct target, ARL5A. In addition to affecting proliferation, the role of miR-202-3p in metastasis is another important aspect that must be considered in future tumor-related research. However, we did not conduct in-depth study on the influence of miR-202-3p on tumor metastasis and only found that it did not significantly affect the migration of HCT-116 or LoVo cells (Supplementary Fig. S1D).

Mature miRNAs are generated from primary precursors encoded by genes involving two subsequent RNA cleavage steps (56). When we overexpressed miR-202-3p by lentiviral overexpression of the pre-miR-202 sequence, the intrinsic mature miR-202-5p was simultaneously overexpressed with a complementary sequence of miR-202-3p. For that reason, we also detected the effect of miR-202-5p on cell growth and found that overexpressing of miR-202-5p did not affect colorectal cancer cell proliferation (Supplementary Fig. S1C). Thus, we excluded the side effect of miR-202-5p overexpression on functional assays using cells that stably expressed miR-202.

Copy number variants (CNV) have been described as notable structural variations in the human genome that affect gene expression and contribute to phenotypic differences (57, 58). However, only a few studies have closely examined the CNVs of miRNAs and recognised their potential consequences. The coding sequence of miR-202-3p is located on chromosome 10q26.3, a region considered a chromosome fragile site that is frequently deleted in endometrial and brain tumors (59, 60). We observed that the copy numbers of pre-miR-202 were decreased in most colorectal cancer or NCT samples and were positively correlated with miR-202-3p expression, most likely leading to the downregulation of miR-202-3p. The analysis of more clinical samples is necessary to confirm these findings.

ARL5A, located on human chromosome 2q23.3, and ARL5A protein in eukaryotes belongs to the ARF family, which are members of the Ras gene superfamily of GTP-binding proteins that are involved in a variety of processes, such as cellular communication, endoplasmic reticulum binding, vesicle transport, and protein synthesis (61, 62). ARL5A is upregulated in liver carcinoma according to a previous report (62). In our study, ARL5A was identified as a direct target of miR-202-3p using a series of assays. We demonstrated that ARL5A is upregulated in colorectal cancer tissues, promotes proliferation, and is a prognostic factor in patients with colorectal cancer. These data suggest, for the first time, that ARL5A is a potential oncogene in colorectal cancer. However, the detailed mechanism by which ARL5A influences colorectal cancer cell growth has not yet been elucidated. Further study about other cell growth–related genes in colorectal cancer (LRIG3 and CPEB4) may be carried through in the future work.

Taken together, miR-202-3p, which is frequently downregulated in human colorectal cancer, was identified as a potent repressor of proliferation. Reexpression of miR-202-3p inhibited colorectal cancer proliferation by silencing its direct target, ARL5A, which was closely related to prognosis of patients with colorectal cancer. Although miRNA research is still at the early stages, the contribution of miRNAs to disease processes is becoming clear. Novel and expanded insights into miRNA deregulation will deepen our understanding of the complicated molecular pathogenesis of colorectal cancer and delineate new options for colorectal cancer treatment.

No potential conflicts of interest were disclosed.

Conception and design: Z. Huang, X. He, X. Du

Development of methodology: Z. Huang, W. Guo, S. Ni, L. Wang, D. Huang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Q. Wang, Z. Huang, X. Xiao, L. Wang, J. Zhang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Q. Wang, Z. Huang, W. Guo, Q. Xu

Writing, review, and/or revision of the manuscript: Q. Wang, Z. Huang, S. Ni, X. He, X. Du

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Q. Wang, X. Xiao, C. Tan, R. Zha, W. Sheng

Study supervision: X. He

The authors thank Didier Trono (School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland) for the generous gift of the psPAX2 and pMD2.G plasmids.

This study was partially supported by grants from the National Natural Science Foundation of China (81071791, 81000867, and 81272299), the Science and Technology Commission of Shanghai Municipality (10DJ1 400501), and the Medical Key Professionals Program of Jiangsu Province (RC2011031).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Bartel
DP
. 
MicroRNAs: target recognition and regulatory functions
.
Cell
2009
;
136
:
215
33
.
2.
Shukla
GC
,
Singh
J
,
Barik
S
. 
MicroRNAs: processing, maturation, target recognition and regulatory functions
.
Mol Cell Pharmacol
2011
;
3
:
83
92
.
3.
Lewis
BP
,
Burge
CB
,
Bartel
DP
. 
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets
.
Cell
2005
;
120
:
15
20
.
4.
Kumar
MS
,
Lu
J
,
Mercer
KL
,
Golub
TR
,
Jacks
T
. 
Impaired microRNA processing enhances cellular transformation and tumorigenesis
.
Nat Genet
2007
;
39
:
673
7
.
5.
Calin
GA
,
Croce
CM
. 
MicroRNA signatures in human cancers
.
Nat Rev Cancer
2006
;
6
:
857
66
.
6.
Huang
Z
,
Huang
D
,
Ni
S
,
Peng
Z
,
Sheng
W
,
Du
X
, et al
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer
.
Int J Cancer
2010
;
127
:
118
26
.
7.
Schepeler
T
,
Reinert
JT
,
Ostenfeld
MS
,
Christensen
LL
,
Silahtaroglu
AN
,
Dyrskjot
L
, et al
Diagnostic and prognostic microRNAs in stage II colon cancer
.
Cancer Res
2008
;
68
:
6416
24
.
8.
Corsini
LR
,
Bronte
G
,
Terrasi
M
,
Amodeo
V
,
Fanale
D
,
Fiorentino
E
, et al
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies
.
Expert Opin Ther Targets
2012
;
16
Suppl 2
:
S103
9
.
9.
Wang
Q
,
Huang
Z
,
Ni
S
,
Xiao
X
,
Xu
Q
,
Wang
L
, et al
Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer
.
PLoS ONE
2012
;
7
:
e44398
.
10.
Jemal
A
,
Bray
F
,
Center
MM
,
Ferlay
J
,
Ward
E
,
Forman
D.
Global cancer statistics
.
CA Cancer J Clin
2011
;
61
:
69
90
.
11.
Ma
Y
,
Zhang
P
,
Yang
J
,
Liu
Z
,
Yang
Z
,
Qin
H
, et al
Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation
.
Int J Cancer
2012
;
130
:
2077
87
.
12.
Kjersem
JB
,
Ikdahl
T
,
Guren
T
,
Skovlund
E
,
Sorbye
H
,
Hamfjord
J
, et al
Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
.
BMC Cancer
2012
;
12
:
534
.
13.
Smits
KM
,
Paranjape
T
,
Nallur
S
,
Wouters
KA
,
Weijenberg
MP
,
Schouten
LJ
, et al
A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer
.
Clin Cancer Res
2011
;
17
:
7723
31
.
14.
Ma
Y
,
Zhang
P
,
Wang
F
,
Zhang
H
,
Yang
Y
,
Shi
C
, et al
Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130
.
Nat Commun
2012
;
3
:
1291
.
15.
Humphreys
KJ
,
Cobiac
L
,
Le Leu
RK
,
Van der Hoek
MB
,
Michael
MZ
, et al
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster
.
Mol Carcinog
2012
;
52
:
459
74
.
16.
Wu
CW
,
Ng
SS
,
Dong
YJ
,
Ng
SC
,
Leung
WW
,
Lee
CW
, et al
Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps
.
Gut
2012
;
61
:
739
45
.
17.
Asangani
IA
,
Rasheed
SA
,
Nikolova
DA
,
Leupold
JH
,
Colburn
NH
,
Post
S
, et al
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
.
Oncogene
2008
;
27
:
2128
36
.
18.
Yamamichi
N
,
Shimomura
R
,
Inada
K
,
Sakurai
K
,
Haraguchi
T
,
Ozaki
Y
, et al
Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development
.
Clin Cancer Res
2009
;
15
:
4009
16
.
19.
Vicinus
B
,
Rubie
C
,
Faust
SK
,
Frick
VO
,
Ghadjar
P
,
Wagner
M
, et al
miR-21 functionally interacts with the 3′UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells
.
Cancer Lett
2012
;
316
:
105
12
.
20.
Schee
K
,
Boye
K
,
Abrahamsen
TW
,
Fodstad
O
,
Flatmark
K
. 
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
.
BMC Cancer
2012
;
12
:
505
.
21.
Xu
XM
,
Qian
JC
,
Deng
ZL
,
Cai
Z
,
Tang
T
,
Wang
P
, et al
Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer
.
Oncol Lett
2012
;
4
:
339
45
.
22.
Huang
Z
,
Huang
S
,
Wang
Q
,
Liang
L
,
Ni
S
,
Wang
L
, et al
MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma
.
Cancer Res
2011
;
71
:
2582
9
.
23.
Strillacci
A
,
Valerii
MC
,
Sansone
P
,
Caggiano
C
,
Sgromo
A
,
Vittori
L
, et al
Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells
.
J Pathol
2013
;
229
:
379
89
.
24.
Chandramouli
A
,
Onyeagucha
BC
,
Mercado-Pimentel
ME
,
Stankova
L
,
Shahin
NA
,
LaFleur
BJ
, et al
MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers
.
Cancer Biol Ther
2012
;
13
:
175
83
.
25.
Nagel
R
,
le Sage
C
,
Diosdado
B
,
van der Waal
M
,
Oude Vrielink
JA
,
Bolijn
A
, et al
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer
.
Cancer Res
2008
;
68
:
5795
802
.
26.
Koga
Y
,
Yasunaga
M
,
Takahashi
A
,
Kuroda
J
,
Moriya
Y
,
Akasu
T
, et al
MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening
.
Cancer Prev Res (Phila)
2010
;
3
:
1435
42
.
27.
Liu
M
,
Lang
N
,
Qiu
M
,
Xu
F
,
Li
Q
,
Tang
Q
, et al
miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells
.
Int J Cancer
2011
;
128
:
1269
79
.
28.
Shen
K
,
Liang
Q
,
Xu
K
,
Cui
D
,
Jiang
L
,
Yin
P
, et al
MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor
.
Biochem Pharmacol
2012
;
84
:
320
30
.
29.
Schepeler
T
,
Holm
A
,
Halvey
P
,
Nordentoft
I
,
Lamy
P
,
Riising
EM
, et al
Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes
.
Oncogene
2012
;
31
:
2750
60
.
30.
Chen
X
,
Guo
X
,
Zhang
H
,
Xiang
Y
,
Chen
J
,
Yin
Y
, et al
Role of miR-143 targeting KRAS in colorectal tumorigenesis
.
Oncogene
2009
;
28
:
1385
92
.
31.
Kent
OA
,
Fox-Talbot
K
,
Halushka
MK
. 
RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets
.
Oncogene.
2012
;
32
:
2576
85
.
32.
Pagliuca
A
,
Valvo
C
,
Fabrizi
E
,
di Martino
S
,
Biffoni
M
,
Runci
D
, et al
Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression
.
Oncogene
2012
;
32
:
4806
13
.
33.
Yin
Y
,
Yan
ZP
,
Lu
NN
,
Xu
Q
,
He
J
,
Qian
X
, et al
Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1
.
Biochim Biophys Acta
2013
;
1829
:
239
47
.
34.
He
YQ
,
Sheng
JQ
,
Ling
XL
,
Fu
L
,
Jin
P
,
Yen
L
, et al
Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells
.
Exp Mol Med
2012
;
44
:
723
32
.
35.
Earle
JS
,
Luthra
R
,
Romans
A
,
Abraham
R
,
Ensor
J
,
Yao
H
, et al
Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma
.
J Mol Diagn
2010
;
12
:
433
40
.
36.
Wang
X
,
Wang
J
,
Ma
H
,
Zhang
J
,
Zhou
X
. 
Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer
.
Med Oncol
2012
;
29
:
919
27
.
37.
Iorio
MV
,
Ferracin
M
,
Liu
CG
,
Veronese
A
,
Spizzo
R
,
Sabbioni
S
, et al
MicroRNA gene expression deregulation in human breast cancer
.
Cancer Res.
2005
;
65
:
7065
70
.
38.
Zhang
Y
,
Dai
Y
,
Huang
Y
,
Ma
L
,
Yin
Y
,
Tang
M
, et al
Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus
.
J Obstet Gynaecol Res
2009
;
35
:
842
9
.
39.
Roush
S
,
Slack
FJ
. 
The let-7 family of microRNAs
.
Trends Cell Biol
2008
;
18
:
505
16
.
40.
Buechner
J
,
Tomte
E
,
Haug
BH
,
Henriksen
JR
,
Lokke
C
,
Flaegstad
T
, et al
Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
.
Br J Cancer
2011
;
105
:
296
303
.
41.
Wang
TL
,
Maierhofer
C
,
Speicher
MR
,
Lengauer
C
,
Vogelstein
B
,
Kinzler
KW
, et al
Digital karyotyping
.
Proc Natl Acad Sci U S A
2002
;
99
:
16156
61
.
42.
Zhao
X
,
Li
C
,
Paez
JG
,
Chin
K
,
Janne
PA
,
Chen
TH
, et al
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays
.
Cancer Res
2004
;
64
:
3060
71
.
43.
Jia
D
,
Wei
L
,
Guo
W
,
Zha
R
,
Bao
M
,
Chen
Z
, et al
Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma
.
Hepatology
2011
;
54
:
1227
36
.
44.
Zhang
T
,
Otevrel
T
,
Gao
Z
,
Ehrlich
SM
,
Fields
JZ
,
Boman
BM
. 
Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer
.
Cancer Res
2001
;
61
:
8664
7
.
45.
Gokmen-Polar
Y
,
Murray
NR
,
Velasco
MA
,
Gatalica
Z
,
Fields
AP
. 
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis
.
Cancer Res
2001
;
61
:
1375
81
.
46.
Tsuchiya
N
,
Ochiai
M
,
Nakashima
K
,
Ubagai
T
,
Sugimura
T
,
Nakagama
H
. 
SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis
.
Cancer Res
2007
;
67
:
9568
76
.
47.
Ding
J
,
Huang
S
,
Wu
S
,
Zhao
Y
,
Liang
L
,
Yan
M
, et al
Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA
.
Nat Cell Biol
2010
;
12
:
390
9
.
48.
Ma
L
,
Teruya-Feldstein
J
,
Weinberg
RA
. 
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
.
Nature.
2007
;
449
:
682
8
.
49.
Korpal
M
,
Ell
BJ
,
Buffa
FM
,
Ibrahim
T
,
Blanco
MA
,
Celia-Terrassa
T
, et al
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization
.
Nat Med
2011
;
17
:
1101
8
.
50.
Tazawa
H
,
Tsuchiya
N
,
Izumiya
M
,
Nakagama
H
. 
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells
.
Proc Natl Acad Sci U S A
2007
;
104
:
15472
7
.
51.
Livak
KJ
,
Schmittgen
TD
. 
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method
.
Methods
2001
;
25
:
402
8
.
52.
Jiang
S
,
Zhang
LF
,
Zhang
HW
,
Hu
S
,
Lu
MH
,
Liang
S
, et al
A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells
.
EMBO J
2012
;
31
:
1985
98
.
53.
Guo
H
,
Hu
X
,
Ge
S
,
Qian
G
,
Zhang
J
. 
Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation
.
Int J Biochem Cell Biol
2012
;
44
:
1465
72
.
54.
Kano
M
,
Seki
N
,
Kikkawa
N
,
Fujimura
L
,
Hoshino
I
,
Akutsu
Y
, et al
miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma
.
Int J Cancer
2010
;
127
:
2804
14
.
55.
Della Vittoria Scarpati
G
,
Falcetta
F
,
Carlomagno
C
,
Ubezio
P
,
Marchini
S
,
De Stefano
A
, et al
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
.
Int J Radiat Oncol Biol Phys
2012
;
83
:
1113
9
.
56.
Lee
YS
,
Nakahara
K
,
Pham
JW
,
Kim
K
,
He
Z
,
Sontheimer
EJ
, et al
Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways
.
Cell.
2004
;
117
:
69
81
.
57.
Golzio
C
,
Willer
J
,
Talkowski
ME
,
Oh
EC
,
Taniguchi
Y
,
Jacquemont
S
, et al
KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant
.
Nature
2012
;
485
:
363
7
.
58.
Cooper
GM
,
Zerr
T
,
Kidd
JM
,
Eichler
EE
,
Nickerson
DA
. 
Systematic assessment of copy number variant detection via genome-wide SNP genotyping
.
Nat Genet
2008
;
40
:
1199
203
.
59.
Peiffer
SL
,
Herzog
TJ
,
Tribune
DJ
,
Mutch
DG
,
Gersell
DJ
,
Goodfellow
PJ
. 
Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers
.
Cancer Res
1995
;
55
:
1922
6
.
60.
Lee
SH
,
Davison
JA
,
Vidal
SM
,
Belouchi
A
. 
Cloning, expression and chromosomal location of NKX6B TO 10Q26, a region frequently deleted in brain tumors
.
Mamm Genome
2001
;
12
:
157
62
.
61.
Wang
ZX
,
Shi
L
,
Liu
JF
,
An
XM
,
Chang
WR
,
Liang
DC
. 
2.0 A crystal structure of human ARL5-GDP3′P, a novel member of the small GTP-binding proteins
.
Biochem Biophys Res Commun
2005
;
332
:
640
5
.
62.
Lin
CY
,
Li
CC
,
Huang
PH
,
Lee
FJ
. 
A developmentally regulated ARF-like 5 protein (ARL5), localized to nuclei and nucleoli, interacts with heterochromatin protein 1
.
J Cell Sci
2002
;
115
:
4433
45
.